About the Authors

Amanda Mocroft

a.mocroft@ucl.ac.uk

Affiliation Department of Infection and Population Health, University College London, London, United Kingdom

Jens D. Lundgren

Affiliation Copenhagen HIV Programme, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Michael Ross

Affiliation Division of Nephrology, Mount Sinai School of Medicine, New York, New York, United States of America

Matthew Law

Affiliation The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia

Peter Reiss

Affiliation Division of Infectious Diseases and Department of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands

Ole Kirk

Affiliation Copenhagen HIV Programme, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

Colette Smith

Affiliation Department of Infection and Population Health, University College London, London, United Kingdom

Deborah Wentworth

Affiliation University of Minnesota, Minneapolis, Minnesota, United States of America

Jacqueline Neuhaus

Affiliation University of Minnesota, Minneapolis, Minnesota, United States of America

Christoph A. Fux

Affiliation Clinic for Infectious Diseases and Hospital Hygiene, Kantonsspital Aarau, Aarau, Switzerland

Olivier Moranne

Affiliation Nephrology Department, Public Health Department, Centre Hospitalier Universitaire de Nice, Nice, France

Phillipe Morlat

Affiliation Université de Bordeaux, INSERM U 897, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France

Margaret A. Johnson

Affiliation Department of HIV Medicine, Royal Free London NHS Foundation Trust, London, United Kingdom

Lene Ryom

Affiliation Copenhagen HIV Programme, Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

D:A:D study group, the Royal Free Hospital Clinic Cohort, and the INSIGHT, SMART, and ESPRIT study groups

Membership of the D:A:D study group, the Royal Free Hospital Clinic Cohort, and the INSIGHT, SMART, and ESPRIT study groups is listed in the Acknowledgments.

Competing Interests

PM: honoraria or travel/meeting expenses from Bristol-Myers Squibb, Gilead, Janssen-Cilag, Merck Sharp & Dohme-Chibret and ViiV Healthcare in the past five years. ML received unrestricted grants to my institution from Boehringer Ingelhiem, Gilead Sciences, Merck Sharp & Dohme, Bristol-Myers Squibb, Janssen-Cilag, ViiV HealthCare. CS has received funds for preparation of Educational Materials from Janssen, Gilead, BMS, ViiV HealthCare, support for attendance at Ad board and support to attend HIV conference from Gilead, funding to conduct study from BMS. OM has received honoraria as a speaker from Abbott and Gilead Sciences, serves on the board of Roche, and had expenses paid by Roche and Baxter for travel, accommodations, and meetings. OK has received honoraria, consultancy, lecture fees, and travel grants from Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp & Dohme, Roche, and ViiV Healthcare, and has served/is serving on Advisory Boards for Gilead Sciences, Merck Sharp & Dohme, and ViiV Healthcare. AM has received honoraria, consultancy, lecture fees, and travel grants from Gilead Sciences, Merck Sharp & Dohme, Boehringer Ingelheim, Pfizer and GSK.

Author Contributions

Conceived and designed the experiments: AM JDL OK LR. Performed the experiments: AM JDL OK LR. Analyzed the data: AM. Enrolled patients: ML PR OK CS DW JN CAF OM PM MAJ. Wrote the first draft of the manuscript: AM JDL LR. Wrote the paper: AM JDL MR ML PR OK CS DW JN CAF OM PM MAJ LR. Agree with manuscript results and conclusions: AM JDL MR ML PR OK CS DW JN CAF OM PM MAJ LR. All authors have read, and confirm that they meet, ICMJE criteria for authorship.